Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina Collaborate on Scalable Clinical Whole-Genome Sequencing Initiative

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Seeking to advance the scope of precision medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina, Inc. are entering into a collaboration to sequence the complete human genomes of thousands of consenting patients, in order to identify genetic alterations driving disease and potentially reveal previously unidentified therapies for treatment. The initiative, which also includes a collaboration between Weill Cornell Medicine, NewYork-Presbyterian Hospital, and the New York Genome Center (NYGC), aims to evaluate the diagnostic potential of whole-genome sequencing at scale, which allows the interrogation of the full genome sequence of a patient’s DNA. The goal is to better understand health problems and potential disease risks of individual patients, and to design more effective treatments, including the choice of specific drugs and their dosing.

Investigators will study the feasibility and viability of large-scale implementation of whole-genome sequencing within an academic medical center that is part

Read More

Pfizer: A ‘New’ Growth Foundation In Genomic Medicine (NYSE:PFE)

Source: Finviz

“With the separation of Consumer Health last year and the expected separation of Upjohn later this year, we are significantly transforming our company. We are evolving from a diversified enterprise to a more focused and innovative biopharma company, from a scientific fast follower to a first-in-class scientific powerhouse. The transformation of this magnitude (began in 2010) could not happen within 1 or 2 years. The increased R&D productivity, as well as the depth and breadth of our pipeline, gave us the confidence to move so quickly over the past year to transform into the new Pfizer.

Albert Bourla Pfizer 2020 R&D Day

Pfizer (PFE) has a storied history dating back to its founding in 1849. Businesses do not thrive for over 170 years without redefining themselves, which is what Pfizer has done. The latest chapter was written in November when they spun off the Upjohn franchise. This followed

Read More

Combining Mixed Reality Tech With Brain Signals Could Improve Rehabilitative Medicine

A new headset and software platform allows researchers and developers of mixed reality programs the opportunity to incorporate signals from the brain and body into their technology, something that has wide potential for use in rehabilitative medicine.

Virtual and augmented reality has already been used to treat patients with a range of psychiatric disorders including ADHD, PTSD and anxiety, but this tech could help improve how effective it is.

ADVERTISEMENT

“You can use virtual reality to put people into those environments and throttle how intense the experience is, but if you could know how intense the reaction is that someone is having, you can decide whether to dial it up a little bit, or dial it down a little bit just to make sure that they’re not overwhelmed by the immersion,” says Conor Russomanno, CEO of OpenBCI, a Brooklyn-based startup that developed the Galea headset.

Another application of the technology,

Read More

Understanding traditional Chinese medicine can help protect species — ScienceDaily

Demystifying traditional Chinese medicine for conservationists could be the key to better protecting endangered species like pangolins, tigers and rhino, according to University of Queensland-led researchers.

UQ PhD candidate Hubert Cheung said efforts to shift entrenched values and beliefs about Chinese medicine are not achieving conservation gains in the short term.

He said a better understanding of traditional practices was critical for conservationists to form more effective strategies.

“The use of endangered species in traditional Chinese medicine threatens species’ survival and is a challenge for conservationists,” Mr Cheung said.

“Pushing messages of inefficacy, providing various forms of scientific evidence or promoting biomedical alternatives doesn’t seem to be drastically influencing decisions and behaviours.

“And, although many practices and treatments continue to be criticised for lacking scientific support, the World Health Organization approved the inclusion of traditional Chinese medicine in its global compendium of medical practices last year.

“The challenge now is

Read More

EU fines drug makers for keeping cheap medicine off market

Boxes of tablets, produced by Teva Pharmaceutical Industries.

Chris Ratcliffe | Bloomberg | Getty Images

The European Union has fined two pharmaceutical companies for colluding to keep a cheap alternative to a sleep disorder medicine off the market for their profit and at the expense of patients.

EU antitrust commissioner, Margrethe Vestager, said that Teva pharmaceuticals and Cephalon, a company it later acquired, must pay 60.5 million euros ($72 million) for agreeing between themselves to delay for years the launch of Teva’s cheaper version of Cephalon’s blockbuster Modafinil. In return for the delay, Teva got beneficial side deals and some payments.

Vestager said that “Teva’s and Cephalon’s pay-for-delay agreement harmed patients and national health systems, depriving them of more affordable medicines.”

Modafinil treats excessive daytime sleepiness and under the brand name Provigil it accounted for more than 40% of Cephalon’s turnover. A cheap alternative would have had a serious impact

Read More

Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak

(Bloomberg) — Vir Biotechnology Inc.’s stock has lost some of its luster after quadrupling earlier this year as competition heats up for Covid-19 antibody therapies. Yet its chief executive officer is looking ahead to the next viral scourge.

Loading...

Load Error

With two well-heeled competitors ahead of it, Vir has pared a February surge to a still impressive 115% leap this year. Eli Lilly & Co.’s antibody treatment received an emergency use authorization on Nov. 9 and Regeneron Pharmaceuticals Inc.’s therapy got its nod over the weekend. Vir’s medicine is unique because it targets a variety of coronaviruses, CEO George Scangos said.

It “has the potential not only to be effective against Covid-19, but it has a reasonable chance of also being effective against the next coronavirus outbreak,” Scangos said in an interview. An interim look at late-stage data for VIR-7831 is expected in January.

Regeneron has touted its two-antibody cocktail

Read More

RESILIENCE Launches to Change the Future of Medicine through Manufacturing Innovation

SAN DIEGO and BOSTON, Nov. 23, 2020 /PRNewswire/ — RESILIENCE (National Resilience, Inc.), a new company building the world’s most advanced biopharmaceutical manufacturing ecosystem, announced its launch today. 

The company will actively invest in developing powerful new technologies to manufacture complex medicines that are defining the future of therapeutics, including cell and gene therapies, viral vectors, vaccines, and proteins. In doing so, it seeks to overcome one of the biggest challenges the biopharmaceutical industry is facing in pioneering novel treatment modalities – manufacturing. RESILIENCE will dramatically increase overall production capacity for these modalities, ensuring that important medicines are accessible to all patients in need and protecting against supply chain disruption.

“We created RESILIENCE to reimagine biopharmaceutical manufacturing through unprecedented investment in technology and a best-in-class team to execute our vision,” said Robert Nelsen, RESILIENCE founder, Chairman of the Board, and managing director at ARCH Venture Partners. “COVID-19 has

Read More

Foundation Medicine Enters into Patent Licensing and Technology Agreement with TwinStrand Biosciences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine today announced it has entered into a non-exclusive agreement to license two foundational patent families from TwinStrand Biosciences, a next-generation DNA sequencing technology company based in Seattle.

The patented TwinStrand Duplex Sequencing™ technology is a biochemistry- and software-based platform that enables researchers and clinicians to detect faint signals of ultra-low frequency DNA mutations often obscured by technical noise.

“Advancing and improving patient care is our highest priority and we’re pleased to work with partners like TwinStrand who share this same goal,” said Cindy Perettie, Foundation Medicine’s chief executive officer. “We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration.”

“We are delighted to partner with Foundation Medicine, a company that shares our patient-centric mission of applying innovative science to advance cancer care globally,” said Jesse Salk, MD, PhD, TwinStrand’s chief executive officer. “We are

Read More

Precision Medicine Market: Future Scope, Revenue Growth, Global Market Size, Market Status, Top key players, end of 2027

The MarketWatch News Department was not involved in the creation of this content.

New York, United States, Wed, 11 Nov 2020 06:07:57 / Comserve Inc. / — The global precision medicine market can be segmented on the basis of product, technology, sequencing technology, application, end user and region.

Recent report published by research nester titled “Precision Medicine Market: Global Demand Analysis & Opportunity Outlook 2027″delivers the detailed overview of the global precision medicine market in terms of market segmentation by product, by technology, by sequencing technology, by application, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The global precision medicine market can be segmented on the basis of product, technology, sequencing technology, application, end user and region. On the basis of product, it is sub-segmented into

Read More

Global Sports Medicine Device Market to 2025 – by Manufacturers, Regions, Technology, and Product Type

DUBLIN, Nov. 10, 2020 /PRNewswire/ — The “Sports Medicine Device Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Product Type” report has been added to ResearchAndMarkets.com’s offering.

This report is a professional and in-depth study on the current state of the global Sports Medicine Device market with a focus on the Chinese market. The report provides key statistics on market of Sports Medicine Device. It is a valuable source of guidance and direction for companies and individuals interested in Sports Medicine Device industry.

Key points of Sports Medicine Device Market Report:
1. The report provides a basic overview of Sports Medicine Device industry including: definition, applications and manufacturing technology.
2. The report explores Global and Chinese major players in Sports Medicine Device market. In this part, the report presents the company profile, product specifications, capacity, production value, and 2015-2020 market shares

Read More